Vaxcyte, Inc. (PCVX) |
|
46.17 -0.72 (-1.54%)
|
01-27 16:00 |
|
Open: |
46.94 |
Pre. Close: |
46.89 |
|
High:
|
47.685 |
Low:
|
46.09 |
|
Volume:
|
346,422 |
Market Cap:
|
3,647(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:59 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 57.59 One year: 67.26 |
| Support: |
Support1: 43.87 Support2: 40.5 |
| Resistance: |
Resistance1: 49.31 Resistance2: 57.59 |
| Pivot: |
45.22  |
| Moving Average: |
MA(5): 45.97 MA(20): 45.69 
MA(100): 37.89 MA(250): 29.29 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 80.8 %D(3): 70.5 |
| RSI: |
RSI(14): 54.3 |
| 52-week: |
High: 49.31 Low: 17.44 |
| Average Vol(K): |
3-Month: 817 (K) 10-Days: 599 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PCVX ] has closed below upper band by 29.1%. Bollinger Bands are 42.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
47.71 - 47.96 |
47.96 - 48.14 |
|
Low:
|
45.53 - 45.78 |
45.78 - 45.98 |
|
Close:
|
45.77 - 46.19 |
46.19 - 46.52 |
|
Company Description |
|
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. |
Headline News |
Sun, 29 Jan 2023
Allspring Global Investments Holdings LLC Acquires 3198 Shares of ... - MarketBeat
Sun, 15 Jan 2023
Vaxcyte: Behind The Recent Rally (NASDAQ:PCVX) - Seeking Alpha
Fri, 13 Jan 2023
Heath Lukatch, a director of Vaxcyte, Inc. (NASDAQ:PCVX), sells ... - Best Stocks
Wed, 11 Jan 2023
Where Does Vaxcyte Inc (PCVX) Stock Fall in the Biotechnology Field After It Has Fallen -7.21% This Week? - InvestorsObserver
Thu, 05 Jan 2023
Vaxcyte's (NASDAQ:PCVX) pneumococcal conjugate vaccine gets ... - Seeking Alpha
Tue, 03 Jan 2023
Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High After ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
79 (M) |
| Shares Float |
67 (M) |
|
% Held by Insiders
|
4.4 (%) |
|
% Held by Institutions
|
75.3 (%) |
|
Shares Short
|
3,440 (K) |
|
Shares Short P.Month
|
3,640 (K) |
Stock Financials |
|
EPS
|
-2.21 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.7 |
|
Return on Equity (ttm)
|
-52.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.2 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-156 (M) |
|
Levered Free Cash Flow
|
-85 (M) |
Stock Valuations |
|
PE Ratio
|
-20.99 |
|
PEG Ratio
|
-11.9 |
|
Price to Book value
|
7.78 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-23.31 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
